Hüseyin ÖZDEN, Gökhan KARACA

The healing effects of prp and thymoquinone on dssinduced inflammatory bowel disease in rats

Aim: Crohn's disease and ulcerative colitis are included in inflammatory bowel disease (IBD). The study aimed to compare the healing effects of two promising therapeutic agents: Platelet Rich-Plasma and Thymoquinone (TQ) on DSS induced IBD.Materials and Methods: The animals were divided into three groups as IBD (n=10), PRP treatment (n=10) and TQ treatment (n=10). Experimental IBD was initiated through the oral intake of 5% Dextran Sodium Sulfate (DSS) in drinking water. PRP (0.5 cc) and thymoquinone dissolved in distilled water (100mg/kg) were daily administered rectally to PRP treated group animals for seven days. All animals were sacrificed and rectal tissue calprotectin, lactoferrin and hydroxyproline levels were assessed on the seventh day. Total antioxidant status (TAS), total oxidant status (TOS) and oxidative stress index (OSI) levels were statistically compared.Results: Rectal tissue calprotectin, lactoferrin and hydroxyproline levels were higher in the IBD group (p

PDF

___

1. Alkan E, Karakas MS, Yildirim B. Mean Platelet Volume in Remitter Patients with Inflammatory Bowel Disease. J Turgut Ozal Med Center 2013;20.
2. Shivashankar R, Tremaine WJ, Harmsen WS, et al. Incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol 2017;15:857-63.
3. Zhang Y-Z, Li Y-Y. Inflammatory bowel disease: pathogenesis. World journal of gastroenterology: WJG 2014;20:91.
4. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011;140:1756-67.
5. Agrawal M, Burisch J, Colombel J-F, et al. Inflammatory bowel diseases among immigrants from low-to highincidence countries: opportunities and considerations. J Crohn's and Colitis 2020;14:267-73.
6. Kopi TA, Shahrokh S, Mirzaei S, et al. The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study. Gastroenterol Hepatol Bed Bench 2019;12:183.
7. Ministro P, Martins D. Fecal biomarkers in inflammatory bowel disease: how, when and why? Expert Rev Gastroenterol Hepatol 2017;11:317-28.
8. Buderus S, Boone JH, Lentze MJ. Fecal lactoferrin: reliable biomarker for intestinal inflammation in pediatric IBD. Gastroenterol Res Pract 2015.
9. Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Dis Primers 2017;14:269-78.
10. Chande N, Costello SP, Limketkai BN, et al. Alternative and Complementary Approaches for the Treatment of Inflammatory Bowel Disease: Evidence From Cochrane Reviews. Inflamm Bowel Dis 2020;26:843- 51.
11. Karaca G, Aydin O, Pehlivanli F, et al. Effectiveness of thymoquinone, zeolite, and platelet-rich plasma in model of corrosive oesophagitis induced in rats. Ann Surg Treat Res 2017;92:396-401.
12. Ocak S, Buk OF, Genc B, et al. The effects of plateletrich-plasma gel application to the colonic anastomosis in hyperthermic intraperitoneal chemotherapy: An experimental rat model. Int Wound J 2019;16:1426- 32.
13. Wang F, Lei X, Zhao Y, et al. Protective role of thymoquinone in sepsis-induced liver injury in BALB/c mice. Exp Ther Med 2019;18:1985-92.
14. Ozden H, Saygun O, Daphan CE, et al. The Effects of Thymoquinone (Kalonji) on Abdominal Adhesion in Experimental Abdominal Adhesive Model. Indian J Surg 2019:1-5.
15. Cobourne-Duval MK, Taka E, Mendonca P, et al. Thymoquinone increases the expression of neuroprotective proteins while decreasing the expression of pro-inflammatory cytokines and the gene expression NFκB pathway signaling targets in LPS/IFNγ-activated BV-2 microglia cells. J Neuroimmunol 2018;320:87-97.
16. Parlar A, Arslan SO. Thymoquinone reduces ischemia and reperfusion-induced intestinal injury in rats, through anti-oxidative and anti-inflammatory effects. Turk J Surg 2020;36:96-105.
17. Wirtz S, Neufert C, Weigmann B, et al. Chemically induced mouse models of intestinal inflammation. Nat Protoc 2007;2:541-6.
18. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of populationbased studies. The Lancet 2017;390:2769-78.
19. Martin JC, Bériou G, Josien R. Dextran sulfate sodium (DSS)-induced acute colitis in the rat. Methods Mol Biol 2016;1371:197-203.
20. Lei X, Liu M, Yang Z, et al. Thymoquinone prevents and ameliorates dextran sulfate sodium-induced colitis in mice. Dig Dis Sci 2012;57:2296-303.
21. Kumar Srivastava A, Khare P, Kumar Nagar H, et al. Hydroxyproline: a potential biochemical marker and its role in the pathogenesis of different diseases. Curr Protein Pept Sci 2016;17:596-602.
22. Heimesaat MM, Heilmann K, Kühl A, et al. The synthetic hydroxyproline-containing collagen analogue (GlyPro-Hyp) 10 ameliorates acute DSS colitis. Eur J Microbiol Immunol (Bp) 2012;2:192-200.
23. Dudzińska E, Gryzinska M, Ognik K, et al. Oxidative stress and effect of treatment on the oxidation product decomposition processes in IBD. Oxid Med Cell Longev.2018.
24. Motor S, Ozturk S, Ozcan O, et al. Evaluation of total antioxidant status, total oxidant status and oxidative stress index in patients with alopecia areata. Int J Clin Exp Med 2014;7:1089.
25. Lugrin J, Rosenblatt-Velin N, Parapanov R, et al. The role of oxidative stress during inflammatory processes. J Biol Chem 2014;395:203-30.
26. Salem ML. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int Immunopharmacol 2005;5:1749-70.
27. Kalus U, Pruss A, Bystron J, et al. Effect of Nigella sativa (black seed) on subjective feeling in patients with allergic diseases. Clinical Trial Phytother Res 2003;17:1209-14.
28. Tekeoglu I, Dogan A, Ediz L, et al. Effects of thymoquinone (volatile oil of black cumin) on rheumatoid arthritis in rat models. Phytother Res 2007;21:895-7.
29. Mahgoub AA. Thymoquinone protects against experimental colitis in rats. Toxicol Lett 2003;143:133- 43.